The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance
The Japan Prize Foundation (President: Hiroshi Komiyama) held an award ceremony on Tuesday, April 16 at the Imperial Hotel Tokyo in Tokyo's Chiyoda Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity.
Prof. Sir Brian J. Hoskins (UK) and Prof. John Michael Wallace (USA), the winners in the field of Resources, Energy, the Environment, and Social Infrastructure, and Prof. Ronald M. Evans (USA), the winner in the field of Medical Science and Pharmaceutical Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal.
Each year, the winners of the Japan prize are recommended by approximately 15,500 prominent scientists and engineers from around the world, and decided by a rigorous examination taking about 1 year. For 2024, The Foundation received 130 nominations for the fields of Resources, Energy, the Environment, and Social Infrastructure, and 198 nominations for the fields of Medical Science and Pharmaceutical Science. This year’s winners were selected from that total of 328 candidates.
The ceremony was attended by about 150 guests, starting with Their Majesties the Emperor and Empress, heads of the three branches of government and other related officials, and representatives from various other elements of society. His Majesty the Emperor delivered remarks, followed by speeches by the three winners, and congratulatory remarks by Hidehisa Otsuji, President of the House of Councilors.
This year's award ceremony can be viewed from the links below.
Japanese Version: https://www.youtube.com/live/9u7k6Al_MlU?si=B8EhDuvEByzFlTKB
English Version: https://www.youtube.com/live/FsNvb9V0ODo?si=vAlfPk94QvCq4Iac
About the Japan Prize
The establishment of the Japan Prize in 1981 was motivated by the Japanese government's desire to create an internationally recognized award that would contribute to scientific and technological development around the world. With the support of numerous donations, the Japan Prize Foundation received endorsement from the Cabinet Office in 1983. The Japan Prize is awarded to scientists and engineers from around the world, who have made creative and dramatic achievements that help progress their fields and contribute significantly to realizing peace and prosperity for all humanity. Researchers in all fields of science and technology are eligible for the award, with two fields selected each year in consideration of current trends in scientific and technological development. In principle, one individual in each field is recognized with the award, and receives a certificate, a medal, and a monetary prize. Each Award Ceremony is attended by Their Majesties the Emperor and Empress, heads of the three branches of government and other related officials, and representatives from various other elements of society.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416718292/en/
Contact information
For inquiries about this release:
The Japan Prize Public Relations Office
E-mail: japanprize@ml.prap.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom